Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

Clinical and Experimental Rheumatology

Volumn 32, Issue 5, 2014, Pages 640-646

  Genre, Fernanda ^a   López Mejías, Raquel ^a   Miranda Filloy, José A ^b   Ubilla, Begoña ^a   Carnero López, Beatriz ^c   Palmou Fontana, Natalia ^d   Gómez Acebo, Inés ^e   Blanco, Ricardo ^a   Rueda Gotor, Javier ^a   Pina, Trinitario ^a   González Juanatey, Carlos ^b   Llorca, Javier ^e   González Gay, Miguel A ^a  

^a IDIVAL   (Spain)

^b Hospital Lucus Augusti   (Spain)

^c HOSPITAL EL BIERZO   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^e UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Ankylosing spondylitis; Anti TNF antibody infliximab; Atherosclerosis; Inflammation; Osteoprotegerin

Indexed keywords

ADIPOCYTOKINE; CHOLESTEROL; INFLIXIMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIINFLAMMATORY AGENT; AUTACOID; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; TNFRSF11B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CELL ACTIVATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE ACTIVITY; DRUG INFUSION; ENDOTHELIUM CELL; FEMALE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; RISK ASSESSMENT; SPINAL PAIN; VISUAL ANALOG SCALE; ADULT; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

ADIPOKINES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; ENDOTHELIAL CELLS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84906974256     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. CAPKIN E, KIRIS A, KARKUCAK M et al.: Investigation of effects of different treatment modalities on structural and functional vessel wall properties in patients with ankylosing spondylitis. Joint Bone Spine 2011; 78: 378-82.
2. GONZALEZ-JUANATEY C, VAZQUEZ-RODRIGUEZ TR, MIRANDA-FILLOY JA et al.: The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009; 88: 358-65.
3. D'ANGELO S, PALAZZI C, CANTINI F et al. Etanercept in spondyloarthopathies. Part II: safety and pharmacoeconomic issues. Clin Exp Rheumatol 2011; 29: 865-70.
4. PALAZZI C, D'ANGELO S, CANTINI F et al. Etanercept in spondyloarthropathies. Part I: current evidence of efficacy. Clin Exp Rheumatol 2011; 29: 858-64.
5. HELDMANN F, BRANDT J, van der HORST-BRUINSMA IE et al. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011; 29: 672-80.
6. van SIJL AM, van EIJK IC, PETERS MJ et al. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis. Ann Rheum Dis 2013 Oct 3 [Epub ahead of print].
7. MIRANDA-FILLOY JA, LLORCA J, CARNERO-LÓPEZ B, GONZÁLEZ-JUANATEY C, BLANCO R, GONZÁLEZ-GAY MA. TNF-α antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clin Exp Rheumatol 2012; 30: 850-5.
8. GENRE F, LÓPEZ-MEJÍAS R, MIRANDA-FILLOY JA et al. Anti-tumour necrosis factor alpha treatment reduces retinol binding protein-4 serum levels in non-diabetic ankylosing spondylitis patients. Ann Rheum Dis 2014; 73: 941-3.
9. MIRANDA-FILLOY JA, LÓPEZ-MEJIAS R, GENRE F et al. Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol 2013; 31: 365-71.
10. MIRANDA-FILLOY JA, LÓPEZ-MEJIAS R, GENRE F et al. Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheum 2013; 31: 538-45.
11. GENRE F, MIRANDA-FILLOY JA, LÓPEZ-MEJIAS R et al. Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF- α antagonist therapy. Clin Exp Rheum 2013; 31: 532-7.
12. GENRE F, LÓPEZ-MEJÍAS R, MIRANDA-FILLOY JA et al. Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy. Clin Exp Rheum 2013; 31: 913-8.
13. GENRE F, LÓPEZ-MEJÍAS R, MIRANDA-FILLOY JA et al. Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheum 2013; 31: 749-55.
14. GENRE F, MIRANDA-FILLOY JA, LÓPEZ-MEJIAS R et al. Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients. Ann Rheum Dis 2013; 72: 1265-7.
15. GENRE F, LÓPEZ-MEJÍAS R, MIRANDA-FILLOY JA et al. Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol 2014; 2: 231-6.
16. HOFBAUER LC, SCHOPPET M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. J Am Med Ass 2004; 28: 490-5.
17. van CAMPENHOUT A, GOLLEDGE J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009; 204: 321-9.
18. SECCHIERO P, CORALLINI F, BELTRAMI AP et al. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 2010; 210: 274-7.
19. SECCHIERO P, RIMONDI E, Di LASIO MG et al. C-reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathway. Clin Cancer Res 2013; 19: 1949-59.
20. Di BARTOLO BA, CARTLAND SP, HARITH HH, BOBRYSHEV YV, SCHOPPET M, KAVURMA MM. TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL. PLoS One 2013; 8: e74211.
21. MANGAN SH, Van CAMPENHOUT A, RUSH C, GOLLEDGE J. Osteoprotegerin up regulates endothelial cell adhesion molecule response to tumor necrosis factor-α associated with induction of angiopoietin-2. Cardiovasc Res 2007; 76: 494-505.
22. ZAULI G, CORALLINI F, BOSSI F et al. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007; 110: 536-43.
23. SANDBERG WJ, YNDESTAD A, OIE E et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: posible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006; 26: 857-63.
24. JONO S, IKARI Y, SHIOI A et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-4.
25. SCHOPPER M, SATTLER AM, SCHAEFER JR, HERZUM M, MAISCH B, HOFBAUER LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88: 1024-8.
26. SEMB AG, UELAND T, AUKRUST P et al. Osteoprotegerin and soluble receptor activator of nuclear factor-κB ligand and risk for coronary events: a nested case - control approach in the Prospective EPIC-Norfolk Population Study 1993-2003. Arterioscler Thromb Vasc Biol 2009; 29: 975-80.
27. KIECHL S, SCHETT G, WENNING G et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-80.
28. BROWNER WS, LUI LY, CUMMINGS SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631-7.
29. ZIEGLER S, KUDLACEK S, LUGAR A, MINAR E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005; 182: 175-80.
30. van der LINDEN S, VALKENBURG HA, CATS A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
31. GONZALEZ-GAY MA, LLORCA J, GARCIA-UNZUETA MT et al. High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 596-603.
32. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, GONZALEZ-JUANATEY C et al. Anti- TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 311-6.
33. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, DE MATIAS JM et al. Influence of anti- TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 373-9.
34. van der HEIJDE D, SIEPER J, MAKSYMOWYCH WP et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 905-8.
35. GARRETT S, JENKINSON T, KENNEDY LG, WHITELOCK H, GAISFORD P, CALIN A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
36. DESSEIN PH, LÓPEZ-MEJIAS R, GONZÁLEZ-JUANATEY C et al. Independent relationship of osteoprotegerin concentrations with endothelial activation and carotid atherosclerosis in patients with severe rheumatoid arthritis. J Rheumatol 2014; 41:429-36.
37. BERG J, SEMB AG, van der HEIJDE D et al. Patients with ankylosing spondylitis have elevated soluble biomarkers of cardiovascular disease compared to controls. Ann Rheum Dis 2013; 72: 528.
38. GANNAGE-YARED MH, FARES F, SEMAAN M, KHALIFE S, JAMBART S. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, Adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxford) 2006; 64: 652-8.
39. POPA C, van den HOOGEN FH, RADSTAKE TR et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1503-7.
40. ROBERTSON J, PETERS MJ, McINNES IB, SATTAR N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 2013; 9: 513-23.
41. GONZALEZ-GAY MA, GONZALEZ-JUANA-TEY C. Inflammation and lipid profile in rheumatoid arthritis: Bridging an apparent paradox. Ann Rheum Dis 2014 (in press)
42. RIDKER PM, COOK N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004; 109: 1955-9.